Australia Primary Biliary Cholangitis (PBC) Therapeutics Market Report 2023 to 2030

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis

$ 3999

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc

ID: IN10AURD059 CATEGORY: Rare Diseases GEOGRAPHY: Australia AUTHOR: Nipun Arora

Buy Now

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis Summary

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market is valued at around $10.4 Mn in 2022 and is projected to reach $25.76 Mn by 2030, exhibiting a CAGR of 12% during the forecast period 2023-2030.

Primary biliary cirrhosis, a chronic liver condition that results in inflammation, fibrosis, and bile duct obstruction, causes the loss of small bile ducts within the liver. An autoimmune condition, an infection, a genetic predisposition, or any combination of these factors may lead to primary biliary cirrhosis. Itching, osteoporosis, high blood cholesterol, and malabsorption of fat and fat-soluble vitamins are all symptoms of primary biliary cirrhosis. It may progress to sicca syndrome, jaundice, hyperpigmentation splenomegaly, hepatomegaly, or Kayser-Fleischer rings. Primary biliary cirrhosis may worsen over time to the point where the liver is completely inoperable. Doctors give medicine to treat the signs and symptoms of PBC and halt the disease's progression. The elimination of bile by the liver is facilitated by ursodiol. This drug frequently enhances liver performance and reduces the progression of liver disease. Ursodeoxycholic acid (UDCA) may be administered in addition to or in place of obeticholic acid if the former proves ineffective or uncomfortable. With this medicine, bile production is decreased but liver bile flow is increased. Depending on the unique circumstances of each patient and the presence of coexisting medical conditions, additional pharmaceutical treatments might be possible. A liver transplant may be necessary if the liver function continues to deteriorate after taking medication.

Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming. Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc.

Market Dynamics

Market Drivers

growing incidence of primary biliary cholangitis

The market is anticipated to grow more quickly due to the rise in primary biliary cholangitis around the world.

Increasing investment in healthcare infrastructure

The rise in healthcare spending is a significant additional factor that encourages the expansion of the primary biliary cholangitis market. Even more, will be impacted by market dynamics by various government organization’s initiatives to upgrade the healthcare infrastructure by boosting funding.

Primary biliary cholangitis will experience growth in the market as a consequence of increased awareness-raising initiatives on the part of both public and private organisations. Additionally, the market for primary biliary cholangitis will grow as a result of sedentary lifestyles, heavy alcohol intake, and smoking addiction.

Market Restraints

On the other hand, market expansion will be constrained by the treatment's high cost. Due to a lack of qualified employees and a lack of healthcare infrastructure in developing countries, the primary biliary cholangitis market may experience challenges. Additionally, the market's rate of expansion will be constrained by severe regulatory requirements and a lack of public awareness.

Key players

Intercept Pharmaceuticals Genfit Madrigal Pharmaceuticals Viking Therapeutics Allergan Alnylam Pharmaceuticals Novartis Pfizer Sanofi Upsher-Smith Laboratories

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Australia Primary Biliary Cholangitis (PBC) Therapeutics Market

By Treatment Type

Liver Transplantation
Drug Therapy
Ursodeoxycholic acid (UDCA)
Obeticholic acid
Fibrates
Budesonide
Others

By Route of Administration

Oral
Parenteral
Other

By Distribution Channels

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.